— Fiscal Impact of Smoking Cessation in Thailand: A Government Perspective Cost-Benefit Analysis Asia Pacific Journal of Public Health 30 (4), 342-350
— Vaccination programs for older adults in an era of demographic change European geriatric medicine, 1-12
— Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report Value in health 21 (10), 1133-1149
— The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value in Health 20 (2), 273-277. Value in Health 20 (2), 273-277.
— Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet Journal of Rare Diseases 12 (1), 10.
— Toxoplasmosis Encephalitis Relapse Rates with Pyrimethamine-based Therapy: Systematic Review and Meta-analysis. Pathogens and Global Health, 1-41.
— Assessment of the broader economic consequences of HPV prevention from a government-perspective: A fiscal analytic approach. PLOS One (2016).
— (2016). Weight status and satisfaction with healthcare received in the US and Georgia. Journal of Georgia Public Health Association, 5(3), 287-293.
— A comparison of average wages with age-specific wages for assessing indirect productivity losses: Analytic simplicity versus analytic precision. The European Journal of Health Economics (2016).
— Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. Health Economics Review 2015, 5:23.
— Universal coverage of IVF pays off. Human Reproduction 2014;29(6):1313-1329
— Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. Gastric Cancer 2014.
— Is the gap between micro and macroeconomic assessments in health care well understood? The case of vaccination and potential remedies.
Journal of Market Access & Health Policy 2014;2: 23897
— Assessing the economic burden and benfit-cost of treating attention-deficit hyperactivity disorder in Germany. J. of Health Economics and Outcomes Research 2013;1(3):212-23.
— Estimating the budget impact of orphan rugs in Sweden and France 2013-2020. Orphanet Journal of Rare Diseases 2014, 9:22.
— The Fiscal Consequences of Changes in Health Status: A ‘Government Perspective’ Modelling Framework.
ISPOR Connections November/December 2013;19(6):pp16-17.
— Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine 2013;31(46):5430-4.
— Assessing the Economic Burden and Benefit-cost of Treating Attention-deficit Hyperactivity Disorder in Germany. J. of Health Economics and Outcomes Research 2013;1(3):212-23.
— Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2 g mesalazine dosing. J. of Crohn's and Colitis in press 2013.
— The Fiscal Consequences of ADHD in Germany: A Quantitative Analysis Based on Differences in Educational Attainment and Lifetime Earnings. The Journal of Mental Health Policy and Economics 2013;16(1):27-33.
— The impact of rotavirus vaccination on discounted net tax revenue in Egypt: A government perspective analysis. PharmacoEconomics 2012:30(8):681-695.
— The economics of mesalazine in active ulcerative colitis and maintenance in The Netherlands. Netherlands Journal of Medicine 2012 Aug;70(6):272-7.
— Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Orphanet Journal of Rare Diseases 2011, 6:62.
— Related Scrip article: Orphan drugs won't bankrupt EU healthcare budgets, 28 October 2011
— Cross-border reproductive care: market forces in action or market failure? An economic perspective. Reproductive BioMedicine Online. Accepted for publication. DOI information: 10.1016/j.rbmo.2011.09.006.
— Kiovig for primary immunodeficiency: Reduced infusion and cost per infusion. Int Immunopharmacol 2011;11(9):1358-61.
— The long-term fiscal impact of funding cuts to Danish public fertility clinics. Reprod Biomed Online 2011;23(7):830-7.
— A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. Journal of Crohn’s and Colitis 2010;4(3):275-282.
— What's on the mind of IVF consumers? Reprod Biomed Online 2009;19(6):767-9.
— The potential economic benefit of maintaining a healthy workforce should be considered when valuing health technologies. Pharmaceutical Marketing – Feature Article; September 2009.
— Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion 2009;80(4):241-6.
— The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: A price-elasticity of demand assessment. Hum Reprod 2009;24(11):2796-800.
— Implementation of National Dyspepsia Guidelines to Reduce Prescribing and Return Patients to Self Care: Results from An Educational Intervention and Prospective Clinical Audit in England. Gastroenterology 2009;136(5 suppl):A-72.
— Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation. BMC Pregnancy and Childbirth 2009;9:23.
— Implementation of national dyspepsia guidelines to reduce prescribing and return patients to self care: results from an educational intervention and prospective clinical audit in England. Pharmacoepidemiology and drug safety 2009;18:1–11.
— Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK. Human Reprod 2009; 24(3):626-32.
— An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis. J Crohns Colitis 2009;3:168-74.
— Long-term fiscal implications of subsidizing in-vitro fertilization in Sweden: a lifetime tax perspective. Scand J Public Health 2008;36:841-9.
— A comparison of treatment failure rates based on starting alginate therapy observed in a large representative longitudinal UK database. Value Health 2008;11(6):A530.
— An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis 2009;3:32-7.
— Measuring Intra-Hospital Clinic Efficiency and Productivity: An Application to a Greek University General Hospital. Eur Res Stud J 2008; XI(1-2):95-110.
— Pricing and reimbursement challenges for new pharmaceuticals and medical devices. www.lifescience-online.com (Oct 2008).
— Price-elasticity of demand for infertility services in Germany. Value Health 2008:11(6).
— Self-diagnosis and health seeking behaviour of women for minor bowel ailments in a large representative United Kingdom (UK) sample population. Gut 2008;57(Suppl I):A271.
— Once daily mesalazine for maintaining remission is cost-saving compared to twice daily mesalazine: An economic evaluation based on the PODIUM randomised controlled trial. Gut 2008;57 (Suppl I):A261.
— Long-term economic benefits attributed to IVF conceived children: A lifetime tax calculation. Am J ManagCare 2008; 14(9):598-604.
— A cost per live birth comparison based on a systematic review of hMG and rFSH randomised trials. Reprod BioMed Online 2008;17(6):756-63.
— Atosiban is cost saving when compared to beta-mimetics in the treatment of preterm labour in Germany. European Congress of Perinatal Medicine, September 2008.
— An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium. Acta Gastroenterol Belg 2008;71:230-36.
— Variation between countries in the perceived use of antiandrogens to prevent flare symptoms: results of a comprehensive survey. EAU Milan 2008.
— The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer. J Clin Oncol 2008;26(Suppl): abstract 16002.
— The influence of Medicare reform on the utilization of anti-androgens in a cohort of patients with prostate cancer in the United States. Am Soc Clin Oncol 2008; abstract 204.
— Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha. Fertil Steril 2009;91(4):1067-76.
— Long-term fiscal implications of subsidizing in-vitro fertilization in Sweden: a lifetime tax perspective. Scand J Public Health 2008;36(8):841-9.
— Assessment of long term economic benefits associated with in-vitro fertilization funding decisions: A simplified lifetime tax calculation. Value Health 2007;10(6):ES7.
— Health Care Services Performance Measurement: Theory, Methods and Empirical Evidence. Eur Res Stud J 2007;X(1-2).
— Measuring Across Hospital Efficiency and Productivity: The Case of Second Regional Health Authority of Attica. Eur Res Stud J 2007;X(1-2).
— Evaluation of improvement in health-related quality of life using oral mesalazine alone or in combination with mesalazine enema in active ulcerative colitis: Results from a randomised controlled trial. Value Health 2007;10(6):PR8.
— Evaluation of the cost-effectiveness of concomitant oral and topical versus oral mesalazine therapy in mild-to-moderate active ulcerative colitis: A decision-analytic model Gut 2007;56:(Suppl III):A149.
— Ledger Money in babies out: Assessing the long-term economic impact of IVF conceived children. J Medical Ethics 2008;34:653-4.
— HP-hMG (Menopur®) is cost-saving in IVF compared to rFSH (Gonal-F®) in an economic evaluation using two large combined randomised controlled trials. Human Reprod 2007;22(7):0-52.
— Cost-saving treatment strategies in cervical ripening/labour induction: A cost comparison of two dinoprostone formulations. J Perinat Med 2007;35:(S139).
— An economic evaluation of HP-hMG and rFSH based on a large randomised trial. Reprod BioMedicine Online 2007;15:500-06.
— Demography is destiny: the long term societal impact of assisted reproduction. Portuguese Infertility Society Annual Meeting (Porto), May 19th 2007 (Invited speaker).
— An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis. Curr Med Res Opin 2007; 23(7):1481-91.
— Costs and effectiveness of highly purified human menopausal gonadotropin (HP-hMG) versus recombinant follitropin alpha (rFSH) in IVF treatment: A United Kingdom discrete event simulation model. 19th World Congress on Infertility and Sterility 2007; Durban (oral presentation).
— The impact of NHS funding decisions for in vitro fertilisation (IVF) on Treasury department revenues: A simplified lifetime net tax calculation. National Institute for Clinical Excellence (NICE) annual meeting, Dec 2006.
— Predictors of health-related quality of life in sufferers with restless legs syndrome: A multi-national study. Sleep Medicine (2006);8(1):73-83.
— An economic evaluation of terlipressin versus alternative vasoactive drug treatments for acute oesophageal variceal bleeding in cirrhotic patients: A UK decision-analytic model. 14th United European Gastroenterology Week; 2006: Berlin (256).
— Present discounted value of children born using IVF compared with naturally conceived children: A simplified UK tax calculation. Hum Rep vol. 21(Suppl 1); 2006 (i74).
— Economic evaluation of vasoactive management options for acute oesophageal variceal bleeding in cirrhotic patients: A Belgian comparison. Ceska a Slovenska Gastrologie a Hepatologie 2006;60,S1:119.
ORPHAN MEDICINES